Open-Label, Concomitant Use of Lamotrigine and Other Medications for Bipolar Disorder
| العنوان: | Open-Label, Concomitant Use of Lamotrigine and Other Medications for Bipolar Disorder |
|---|---|
| المؤلفون: | Charles L. Bowden, Suzanne Edwards, Gary Evoniuk |
| المصدر: | CNS Spectrums. 13:75-83 |
| بيانات النشر: | Cambridge University Press (CUP), 2008. |
| سنة النشر: | 2008 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, Bipolar Disorder, Bipolar I disorder, Lithium (medication), medicine.drug_class, Serotonin reuptake inhibitor, Atypical antipsychotic, Lamotrigine, Treatment of bipolar disorder, Double-Blind Method, Antimanic Agents, Internal medicine, medicine, Humans, Drug Interactions, Bipolar disorder, Psychiatric Status Rating Scales, Triazines, business.industry, medicine.disease, Psychiatry and Mental health, Treatment Outcome, Tolerability, Lithium Compounds, Anticonvulsants, Drug Therapy, Combination, Female, Neurology (clinical), business, Selective Serotonin Reuptake Inhibitors, Antipsychotic Agents, medicine.drug |
| الوصف: | Objective:A post-hoc, descriptive analysis was undertaken to assess the tolerability of and changes in psychiatric rating scales with lamotrigine (LTG) administered concomitantly with commonly prescribed bipolar medications.Methods:During the 8- to 16-week, open-label, preliminary phase of two large clinical trials of patients (N=1,305) with bipolar I disorder, LTG was added to each patient's existing psychotropic regimen. Medications for acute symptoms could have been added and later discontinued to achieve LTG monotherapy. Data were compared for patients taking LTG with or without concomitant valproate, lithium, any atypical antipsychotic, or any selective serotonin reuptake inhibitor.Results:The percentages of patients with any reported adverse event and reported adverse events of mood symptoms or rash were comparable between those taking LTG with or without other concomitant bipolar medications. Adverse events in >10% of patients in at least one subgroup were headache, infection, nausea, rash, influenza, diarrhea, dizziness, and somnolence. Baseline scores on psychiatric rating scales improved similarly with LTG co-administered with other bipolar medications, and the pattern of results did not differ by baseline polarity of mood symptoms.Conclusion:LTG co-administered with valproate, lithium, an atypical antipsychotic, or a selective serotonin reuptake inhibitor in the treatment of bipolar disorder seemed to be well tolerated and was associated with clinical improvement. |
| تدمد: | 2165-6509 1092-8529 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d70eef31dce654ef8e92762a1126dd11 https://doi.org/10.1017/s1092852900016187 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi.dedup.....d70eef31dce654ef8e92762a1126dd11 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 21656509 10928529 |
|---|